Mitsubishi UFJ Trust & Banking Corp Purchases 26,129 Shares of Elanco Animal Health Incorporated $ELAN

Mitsubishi UFJ Trust & Banking Corp increased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 36.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 97,803 shares of the company’s stock after buying an additional 26,129 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Elanco Animal Health were worth $2,213,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. SJS Investment Consulting Inc. boosted its holdings in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares during the period. Huntington National Bank boosted its holdings in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its holdings in Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after buying an additional 900 shares during the period. Farther Finance Advisors LLC boosted its holdings in Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after buying an additional 951 shares during the period. Finally, Fifth Third Bancorp boosted its holdings in Elanco Animal Health by 3,018.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after buying an additional 2,807 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 0.1%

ELAN opened at $22.54 on Tuesday. The firm has a 50-day simple moving average of $23.86 and a two-hundred day simple moving average of $23.27. Elanco Animal Health Incorporated has a 52 week low of $9.42 and a 52 week high of $27.72. The company has a market capitalization of $11.21 billion, a PE ratio of -46.96, a price-to-earnings-growth ratio of 2.87 and a beta of 1.69. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business’s revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Analysts forecast that Elanco Animal Health Incorporated will post 1.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ELAN has been the subject of several research reports. Leerink Partners increased their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. increased their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, February 19th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 18th. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Finally, Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $24.00 to $30.00 in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $27.90.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.